RBF Capital’s CRISPR Therapeutics CRSP Stock Holding History

RBF Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,000	Closed	-$612K	–	449
2020 Q4	$612K	Buy	+4,000	New	+$473K	0.05%	255

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RBF Capital's CRSP Position: Q1 2021 in Review

RBF Capital sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 4,000 shares — an estimated $612K sold.

RBF Capital first reported a position in CRSP in Q4 2020 and held it in 1 quarter. The position peaked at $612K in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

RBF Capital reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
RBF Capital sold 4,000 CRISPR Therapeutics shares in Q1 2021, an estimated $612K.
RBF Capital first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 1 quarter.
RBF Capital's CRISPR Therapeutics position peaked at $612K in Q4 2020.
443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on RBF Capital's 13F filing for Q1 2021, filed 17 May 2021.